Systemic sclerosis & Raynaud's
BLyS/APRIL dual inhibition for systemic sclerosis: a single-centre, single-arm, open-label clinical trial of telitacicept
Authors' conclusion
Telitacicept has the potential to be a safe and effective treatment for patients with SSc
Study context
- Population
- Systemic sclerosis (SSc) patients inadequately responding to traditional immunosuppressants
- Participants
- 8 participants
- Comparison
- Telitacicept 160 mg weekly for 24 weeks added to stable background immunosuppression; week 24 vs baseline
- Telitaciceptn = eight
- Outcome
- Changes in the median mRSS
- Follow-up
- Week 24
Methodological detailssingle-centre, open-label
- Single-centre
- Open-label
Main finding
As reported in the abstract
mRSS, change from baseline
Mean mRSS at baseline (±)
18.9±5.8
Mean mRSS at week 24 (±), vs baseline p=0.003
10.8±5.8
Further findings
mRSS at week 12
- Mean mRSS at week 12 (±), vs baseline 18.9±5.8, p=0.008
- 12.5±5.0
SCTC-DI score, ScleroID questionnaire score and SF-36 physical score · week 24
- Improved
- P < 0.05
CRISS score
- CRISS score, indicating clinical improvement (higher scores better)
- 0.75
CD19+ B cells
- Decreased from 10.2% to 4.3%
- P = 0.006
Transitional B cells
- Decreased from 6.8% to 1.4 %
- P = 0.005
Naive B cells
- Decreased from 8.9% to 3.0%
- P = 0.001
Immature B cells
- Increased from 0.10 % to 0.24%
- P = 0.03
Serum immunoglobulins (IgG, IgA, IgM) · week 24
- Decreased
- P < 0.05
Haemoglobin · week 12
- Increased
- P = 0.013
HRCT score for pulmonary fibrosis · week 24
- Declined
- P = 0.036
Titre of SSc-specific antibodies
- Decrease observed in six out of eight patients
- 6/8
Deaths
- No deaths occurred
Safety
Serious adverse events
- No serious adverse events occurred
Adverse effects
- Mainly hypogammaglobulinaemia, respiratory tract infection, urinary tract infections and rash
Original publication
BLyS/APRIL dual inhibition for systemic sclerosis: a single-centre, single-arm, open-label clinical trial of telitacicept. Clin Exp Rheumatol. Published 15 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →